Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
European Medicines Agency will move to Amsterdam

In the end, after three rounds of voting, it came down to a proverbial coin flip between the Dutch capital and an Italian fashion hub. The European Medicines Agency (EMA), charged with evaluating human and animal medicinal products for the European Union, will relocate to Amsterdam after it was selected in a draw of lots between it and Milan.

Published
4 hours ago
From
Science
Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid US outbreaks

Since March, the CDC’s Division of Viral Hepatitis has identified hepatitis A outbreaks in several cities in California, Michigan and Utah, especially among people who are homeless and people who use drugs. Over the past six months, those ongoing outbreaks have resulted in supply stress for vaccine makers Merck and GSK, which sell U.S.-licensed hepatitis A shots Vaqta and Havrix, respectively.

Published
15 November 2017
From
FiercePharma
Danish court invalidates Gilead SPC

The Danish Maritime and Commercial High Court has invalidated a supplementary protection certificate (SPC) owned by Gilead. On October 26, the court rejected Gilead’s motion for an injunction against generics maker Accord.

Published
10 November 2017
From
Life Sciences Intellectual Property Review
Gilead loss of generic HIV drug battle a boost for gay community

Published
09 November 2017
From
The Irish Times
Why do some HIV drugs cost so much in the US? Pharma, insurers, advocacy groups and consumers weigh in

As open enrollment begins November 1, millions of Americans are comparing insurance plans available on the Affordable Care Act insurance marketplace. Prescription copayments and which medications a health plan covers are key considerations for people living with HIV and for those taking regular prescription medications. The cost to the consumer is very different, however, from the price that insurers negotiate with pharmaceutical companies, and the debate around drug pricing has hit national headlines in recent years with cases like EpiPen and Daraprim. Drug pricing is a complicated issue, with pharmaceutical companies on one side, patient activists on the other, and consumers oftentimes stuck somewhere in the middle.

Published
03 November 2017
From
BETA blog
GSK and Gilead go head to head as HIV drugs enter new phase

Gilead Sciences and GlaxoSmithKline are heading for an HIV showdown, pushing rival treatment visions and competing products that are expected to hit the market in the next few months. Gilead is likely to secure the bigger near-term win, as it builds on a 20-year-old strategy of combining three drugs to control the AIDS virus, while GSK is placing a longer bet that its core drug is potent enough to work with just one other.

Published
02 November 2017
From
Reuters
MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, sofosbuvir and daclatasvir, for as low as US$1.40 per day, or US$120 per 12-week treatment course.

Published
31 October 2017
From
Intellectual Property Watch
Gilead HCV drug sales down in 2017 third quarter compared with 2016

Gilead announced that combined third-quarter sales for Harvoni, Sovaldi, Epclusa and Vosevi were $2.2 billion compared with $3.3 billion the third quarter of 2016, related to fewer patients initiating treatment and increased drug competition.

Published
31 October 2017
From
Healio
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty

A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.

Published
26 October 2017
From
Intellectual Property Watch
HIV pills and new lung drugs keep GSK on track in third-quarter

GlaxoSmithKline (GSK.L) grew sales 4 percent in the third quarter, helped by demand for new products, keeping it on track to deliver on full-year financial targets as new Chief Executive Emma Walmsley refocuses the drugs pipeline.

Published
25 October 2017
From
Reuters
← First12345...101Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.